 RADNOR, Pa., Aug. 9, 2021 PRNewswire -- NRx Pharmaceuticals NRx Nasdaq: NRXP, a clinical stage, global biopharmaceutical company today announced it is initiating a phase 2b dose-confirmatory trial of the BriLifeTM vaccine against COVID-19 in the Nation of Georgia. 